• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Eli Lilly’s tirzepatide injection results could trigger another bull run: Here’s why

by August 1, 2024
written by August 1, 2024

Eli Lilly and Company (NYSE: LLY) recently announced promising results from its SUMMIT phase 3 trials, focusing on the efficacy of the tirzepatide injection.

The positive findings have sparked investor interest, driving the stock up by 3% today.

These results are not only significant for Eli Lilly but also hold potential for millions of patients suffering from heart failure with preserved ejection fraction (HFpEF) and obesity.

Promising trial results

The SUMMIT phase 3 trial results revealed that tirzepatide reduced the risk of heart failure outcomes by 38% compared to a placebo. Additionally, all key secondary endpoints were successfully met, including:

It reduced the risk of heart failure outcomes by 38% compared to placebo.

All l key secondary endpoints were met successfully. These included exercise capacity, mean body weight reduction from baseline at 52 weeks, and reduction in the inflammation marker high-sensitivity C-reactive protein.

For the efficacy estimand, it led to a 15.7% weight reduction compared to 2.2% for placebo.

For the treatment regimen estimand, it led to a 13.9% reduction in body weight compared to 2.2% for placebo.

Why is this result significant?

The result carries weight because HFpEF (heart failure with preserved ejection fraction) accounts for 50% of all heart failure cases. In the US, 60% of those also suffer from obesity.

It is a condition where the left pumping chamber of the heart becomes stiff and is unable to fill normally. Thanks to tirzepatide, this problem can finally be addressed.

The company will now submit the SUMMIT study findings to the FDA and hope for a positive response from them. If the drug is approved, tirzepatide could become the cornerstone of Eli Lilly’s portfolio and substantially boost revenue.

CEO says shortage of tirzepatide should end soon

CEO David Ricks had more good news for the investors today as he claimed the shortage of tirzepatide should end soon. He made this revelation during an interview with Bloomberg.

Some doses of LLY’s weight loss drugs Zepbound and Mounjaro have been on FDA’s shortage list for some time now. In fact, Mounjaro is on that list since since 2022.

The company had initially stated in April that it expects the supply to remain tight. However, the CEO’s comments have increased investor confidence and hopes.

What does the chart say?

LLY stock has been on a downslide recently as the US market corrects across the board. The announcement of the drug trial comes at a time when the stock was about to test a key support level as shown in the chart below.

The trendline that started over a year ago was about to be approached but the stock price never reached there. Traders will probably still wait for a retesting of that line but investors, on the back of above positive developments will hope that the retesting isn’t needed and the stock can continue its upward journey.

As the market tumbles today, investors will find comfort in the fact that LLY stock is still up 3%. Only time will tell if that’s temporary though.

The post Eli Lilly’s tirzepatide injection results could trigger another bull run: Here’s why appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
CleanSpark expands in Wyoming, overtakes Riot as second-largest Bitcoin miner in US
next post
Riot Platforms stock has a 71% upside: analyst

related articles

Asian markets close: Nikkei, Kospi down; Sensex closes...

May 19, 2025

Qualcomm unveils AI chips for data centres with...

May 19, 2025

Best crypto to buy now: Bitcoin Pepe leads...

May 19, 2025

JPMorgan cuts Netflix rating, citing balanced risk-reward post-rally;...

May 19, 2025

Bitcoin ETF open interest dips 5% to $29.47B...

May 19, 2025

US stocks slip in the red on Monday:...

May 19, 2025

Should Klarna IPO remain on watch list after...

May 19, 2025

Why this brokerage downgraded UnitedHealth’s rating to ‘hold’

May 19, 2025

Nvidia opens NVLink Fusion ecosystem, expands Taiwan footprint...

May 19, 2025

Cathie Wood says Trump’s tariffs could unlock tech...

May 19, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Short TXN: Texas Instruments Faces Rejection at $205, Short-Term Retest of $200 Expected

    July 18, 2024
  • Mike Johnson re-elected speaker: Here were the top three moments of the dramatic vote

    January 4, 2025
  • Rapper who was pardoned had this to say about president in 2017

    May 29, 2025
  • Disney tops quarterly profit estimates but starts to lose Disney+ streaming subscribers

    February 6, 2025
  • ‘Intensely loyal’ Jill Biden aide despised by White House staffers, new book claims

    May 28, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,721)
  • Investing (624)
  • Stock (773)

Latest Posts

  • S&P 500 and Nasdaq under pressure from global events

    August 6, 2024
  • Deciphering Donald Trump: How his rhetoric sends different messages

    February 25, 2025
  • Biden’s Meta ‘censorship’ revelations ‘vindicated’ Alito dissent in RFK Jr case

    January 16, 2025

Recent Posts

  • Russian missiles rained down on Ukraine just ahead of Treasury Secretary Scott Bessent’s visit

    February 12, 2025
  • Bitcoin mining company Cipher considering sale after takeover bid

    July 18, 2024
  • DOGE’s plans to offload government buildings supported by former GSA official

    March 16, 2025

Editor’s Pick

  • Cathie Wood’s Ark Invest sold Roku, Robinhood on Thursday: here’s what it bought

    February 14, 2025
  • Delta CEO offers employees free flights after CrowdStrike-Microsoft chaos

    August 5, 2024
  • Jimmy Carter’s funeral will bring all five living presidents together in Washington, D.C.

    January 9, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock